|
The acceptance Intake of Nitroso-Propranolol
|
|
16
|
3582
|
May 24, 2023
|
|
Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines
|
|
2
|
1005
|
May 23, 2023
|
|
Setting limit for Nitrite and Nitrate in water used for Active Ingredients synthesis
|
|
2
|
1398
|
May 23, 2023
|
|
Nitroso Furosemide
|
|
1
|
882
|
May 20, 2023
|
|
Indigo carmine as secondary amine?
|
|
7
|
724
|
May 16, 2023
|
|
Nitrosamines in ICH S9
|
|
8
|
1523
|
May 15, 2023
|
|
AI for NDSRIs of Terbinafin hydrochloride and Impurity A
|
|
4
|
923
|
May 14, 2023
|
|
Understanding the Impact Nitrosamine Impurities Can Have in the Work of Pharmacy Professionals
|
|
0
|
477
|
May 11, 2023
|
|
Ministry of Food and Drug Safety of the Republic of Korea detected N-Nitroso-Atenolol in atenolol formulation products
|
|
5
|
1191
|
May 7, 2023
|
|
Indian Pharmacopoeia introduces a new General Chapter on Nitrosamine Impurities in its 2022 edition
|
|
4
|
1729
|
May 6, 2023
|
|
IPEC India survey on excipients
|
|
0
|
427
|
May 5, 2023
|
|
Nitrosamine Risk Assessment for Drug Product Manufacturer with 50+ APIs
|
|
4
|
671
|
May 4, 2023
|
|
Instem SOT 2023 Presentation on Assessing N-nitrosamines Potency Classes
|
|
1
|
667
|
May 2, 2023
|
|
Impact of N‑nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer
|
|
1
|
431
|
May 2, 2023
|
|
Nuevas inspecciones en busca de Nitrosaminas y Genotóxicos en API no evaluados
|
|
1
|
755
|
May 1, 2023
|
|
ECHA has provided Occupational Exposure Limit (OEL) values for most commonly used nitrosamines
|
|
0
|
632
|
April 27, 2023
|
|
APEC - Safeguarding patients from Impurities in the drug supply chain - Nitrosamines
|
|
0
|
467
|
April 26, 2023
|
|
The Great Nitrosamine Audit: how many more drugs will disappear from our shelves?
|
|
2
|
769
|
April 26, 2023
|
|
A Consideration of the Extent That Tertiary Amines Can Form N-Nitroso Dialkylamines in Pharmaceutical Products
|
|
1
|
1227
|
April 25, 2023
|
|
EFPIA Position paper for NDSRIs of beta-blockers and beta-agonists / ACE inhibitors / dihydropyridine
|
|
1
|
1327
|
April 24, 2023
|
|
Health Canada: Guidance on Nitrosamine Impurities in Medications
|
|
0
|
1108
|
April 23, 2023
|
|
Nitrosamine in Antabuse
|
|
7
|
1402
|
April 18, 2023
|
|
EMA Nitrosamine Q&A Rev15 published
|
|
12
|
2644
|
April 18, 2023
|
|
Drawing a line: Where might the cohort of concern end?
|
|
5
|
1001
|
April 18, 2023
|
|
📚 Nitrosamine Exchange - Analytical Hub
|
|
13
|
2705
|
April 17, 2023
|
|
Generic Drugs Forum (GDF) 2023: Celebrating 10 Years of the GDF
|
|
1
|
555
|
April 16, 2023
|
|
Hydrazide Nitrosamine Formation
|
|
9
|
1508
|
April 16, 2023
|
|
7th Impurities: Genotoxic, Nitrosamine & Beyond Summit 15-16 March- Italy& Online
|
|
6
|
756
|
April 16, 2023
|
|
Product change over cleaning
|
|
3
|
515
|
April 11, 2023
|
|
N-Nitrosobupropion
|
|
4
|
1532
|
April 10, 2023
|